Skip to content
PPP173173173

Drawing based on the label description. No photo yet.

“5 mg amlodipine /160 mg valsartan /25 mg hydrochlorothiazide Tablets - Yellow, film-coated, oval shaped biconvex tablets debossed with "P" on one side of the tablet and "173" on the other”

P 173 pill

Pill with imprint P 173 is yellow, oval, 8 mm and has been identified as Amlodipine Besylate Valsartan Hydrochlorothiazide 5 mg / 160 mg / 25 mg. It is used for high blood pressure. It is supplied by Strides Pharma Science Limited.

Amlodipine Besylate Valsartan Hydrochlorothiazide 5 mg / 160 mg / 25 mg

Imprint
P 173
Strength
Amlodipine 5 mg / Valsartan 160 mg / Hydrochlorothiazide 25 mg
Used for
High blood pressure
Color
Yellow
Shape
Oval
Size
8 mm
Score
No score line
Form
Tablet, film coated
Manufacturer
Strides Pharma Science Limited
NDC
64380-198, 64380-198-01, 64380-198-02, 64380-198-03, 51407-669, 51407-669-30

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Amlodipine Besylate Valsartan Hydrochlorothiazide pills and guides

What is Amlodipine Besylate Valsartan Hydrochlorothiazide used for?

Amlodipine Besylate Valsartan Hydrochlorothiazide is used for high blood pressure.

Official uses from the US prescribing label

Amlodipine/valsartan/hydrochlorothiazide is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine/valsartan/hydrochlorothiazide.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Limitation of Use

Amlodipine/valsartan/hydrochlorothiazide is not indicated for the initial therapy of hypertension.

From the FDA-approved label on DailyMed (published Jun 12, 2025).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows P and the other side shows 173.
  • It is yellow, oval, 8 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold under the brand name Amlodipine, Valsartan, Hydrochlorothiazide.

Ingredients

Active: Amlodipine Besylate, Valsartan, Hydrochlorothiazide

Inactive: Cellulose, Microcrystalline, Crospovidone, Magnesium Stearate, Titanium Dioxide, D&c Yellow No. 10, Triacetin, Fd&c Yellow No. 6, Silicon Dioxide, Lactose Monohydrate, Hypromellose, Unspecified

Also distributed by

Golden State Medical Supply, Inc.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Amlodipine Besylate Valsartan Hydrochlorothiazide pills